Longitudinal Assessment of Morbidity and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Retrospective Analysis of a Multicenter Phase III Study

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 6, 2009, Pages 749-756

  Carnevale Schianca, Fabrizio ^a   Leisenring, Wendy ^a,b   Martin, Paul J ^a,b   Furlong, Terry ^a   Schoch, Gary ^a   Anasetti, Claudio ^a,b   Appelbaum, Frederick R ^a,b   Carpenter, Paul A ^a   Deeg, H Joachim ^a,b   Kiem, Hans Peter ^a,b   Storb, Rainer ^a,b   McDonald, George B ^a,b   Nash, Richard A ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cyclosporine; Graft versus host disease; Tacrolimus

Indexed keywords

ANTIFUNGAL AGENT; CORTICOSTEROID; CYCLOSPORIN; METHOTREXATE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; GASTROINTESTINAL DISEASE; GRAFT SURVIVAL; HLA MATCHING; HUMAN; LIVER DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MORBIDITY; MYCOSIS; MYELOABLATIVE CONDITIONING; OPEN STUDY; RETROSPECTIVE STUDY; SKIN DISEASE; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; METHOTREXATE; ORGAN SPECIFICITY; POSTOPERATIVE COMPLICATIONS; SKIN DISEASES; TACROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 65549107728     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.03.009     Document Type: Article

References (23)

1. Sullivan K.M. Graft-vs-host disease. In: Blume K.G., Forman S.J., and Appelbaum F.R. (Eds). Thomas' Hematopoietic Cell Transplantation (2004), Blackwell, Oxford, UK 635-664
2. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974) 295-304
3. Przepiorka D., Weisdorf D., Martin P., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
4. Thomas E.D., Storb R., Clift R.A., et al. Bone marrow transplantation. N Engl J Med 292 (1975) 832-843 895-902
5. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 97 (1997) 855-864
6. Atkinson K., Horowitz M.M., Biggs J.C., et al. The clinical diagnosis of acute graft-versus-host disease: a diversity of views amongst marrow transplant centers. Bone Marrow Transplant 3 (1988) 5-10
7. Martin P., Nash R., Sanders J., et al. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant 21 (1998) 273-279
8. Martin P.J., Schoch G., Gooley T., et al. Methods for assessment of graft-versus-host disease [letter]. Blood 92 (1998) 3479-3481
9. Leisenring W.M., Martin P.J., Petersdorf E.W., et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 108 (2006) 749-755
10. Noseworthy J.H., Ebers G.C., Vandervoort M.K., et al. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 44 (1994) 16-20
11. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 314 (1986) 729-735
12. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92 (1998) 2303-2314
13. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96 (2000) 2062-2068
14. Deeg H.J., Lin D., Leisenring W., et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 89 (1997) 3880-3887
15. Chao N.J., Schmidt G.M., Niland J.C., et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329 (1993) 1225-1230
16. Wagner J.E., Thompson J.S., Carter S.L., et al. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-Cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 366 (2005) 733-741
17. Martin P.J., and Nash R.A. Pitfalls in the design of clinical trials for prevention or treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 12 (2006) 31-36
18. Al-Ghamdi H., Leisenring W., Bensinger W.I., et al. A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interest. Br J Haematol 113 (2001) 461-469
19. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344 (2001) 175-181
20. Liang K.-Y., and Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 73 (1986) 13-22
21. Agresti A. Multinomial response models. Categorical Data Analysis (1990), Wiley, New York 322-324
22. Cahn J.Y., Klein J.P., Lee S.J., et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 106 (2005) 1495-1500
23. Martin P.J., McDonald G.B., Sanders J.E., et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 10 (2004) 320-327